Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Richard A Preston, Barry R. Davis, Jan N. Basile, Paul K. Whelton, Robert J. Weiss, Arnaud Bastien, Donald L. Courtney, Bruce P. Hamilton, Kent Kirchner, Gail T. Louis, Tamrat M. Retta, Donald G. Vidt

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9years) by randomized groups: chlorthalidone, 12.5-25mg/d (n=15,255), amlodipine 2.5-10mg/d (n=9048), or lisinopril 10-40mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83mm Hg (27% control) to 134/ 76mm Hg (chlorthalidone, 68% control), 135/75mm Hg (amlodipine, 66% control), and 136/76mm Hg (lisinopril, 61% control) by 5years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP <140/90mm Hg in a majority of patients.

Original languageEnglish
Pages (from-to)751-760
Number of pages10
JournalJournal of clinical hypertension
Volume10
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Chlorthalidone
Antihypertensive Agents
Lisinopril
Amlodipine
Myocardial Infarction
Blood Pressure
Lipids
Control Groups
Therapeutics
Hypertension
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). / Cushman, William C.; Ford, Charles E.; Einhorn, Paula T.; Wright, Jackson T.; Preston, Richard A; Davis, Barry R.; Basile, Jan N.; Whelton, Paul K.; Weiss, Robert J.; Bastien, Arnaud; Courtney, Donald L.; Hamilton, Bruce P.; Kirchner, Kent; Louis, Gail T.; Retta, Tamrat M.; Vidt, Donald G.

In: Journal of clinical hypertension, Vol. 10, No. 10, 01.10.2008, p. 751-760.

Research output: Contribution to journalArticle

Cushman, WC, Ford, CE, Einhorn, PT, Wright, JT, Preston, RA, Davis, BR, Basile, JN, Whelton, PK, Weiss, RJ, Bastien, A, Courtney, DL, Hamilton, BP, Kirchner, K, Louis, GT, Retta, TM & Vidt, DG 2008, 'Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)', Journal of clinical hypertension, vol. 10, no. 10, pp. 751-760. https://doi.org/10.1111/j.1751-7176.2008.00015.x
Cushman, William C. ; Ford, Charles E. ; Einhorn, Paula T. ; Wright, Jackson T. ; Preston, Richard A ; Davis, Barry R. ; Basile, Jan N. ; Whelton, Paul K. ; Weiss, Robert J. ; Bastien, Arnaud ; Courtney, Donald L. ; Hamilton, Bruce P. ; Kirchner, Kent ; Louis, Gail T. ; Retta, Tamrat M. ; Vidt, Donald G. / Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). In: Journal of clinical hypertension. 2008 ; Vol. 10, No. 10. pp. 751-760.
@article{fe96bfc642e44e17b0434f8cba0e936e,
title = "Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)",
abstract = "Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9years) by randomized groups: chlorthalidone, 12.5-25mg/d (n=15,255), amlodipine 2.5-10mg/d (n=9048), or lisinopril 10-40mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83mm Hg (27{\%} control) to 134/ 76mm Hg (chlorthalidone, 68{\%} control), 135/75mm Hg (amlodipine, 66{\%} control), and 136/76mm Hg (lisinopril, 61{\%} control) by 5years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28{\%} (chlorthalidone), 24{\%} (amlodipine), and 24{\%} (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP <140/90mm Hg in a majority of patients.",
author = "Cushman, {William C.} and Ford, {Charles E.} and Einhorn, {Paula T.} and Wright, {Jackson T.} and Preston, {Richard A} and Davis, {Barry R.} and Basile, {Jan N.} and Whelton, {Paul K.} and Weiss, {Robert J.} and Arnaud Bastien and Courtney, {Donald L.} and Hamilton, {Bruce P.} and Kent Kirchner and Louis, {Gail T.} and Retta, {Tamrat M.} and Vidt, {Donald G.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1111/j.1751-7176.2008.00015.x",
language = "English",
volume = "10",
pages = "751--760",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

AU - Cushman, William C.

AU - Ford, Charles E.

AU - Einhorn, Paula T.

AU - Wright, Jackson T.

AU - Preston, Richard A

AU - Davis, Barry R.

AU - Basile, Jan N.

AU - Whelton, Paul K.

AU - Weiss, Robert J.

AU - Bastien, Arnaud

AU - Courtney, Donald L.

AU - Hamilton, Bruce P.

AU - Kirchner, Kent

AU - Louis, Gail T.

AU - Retta, Tamrat M.

AU - Vidt, Donald G.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9years) by randomized groups: chlorthalidone, 12.5-25mg/d (n=15,255), amlodipine 2.5-10mg/d (n=9048), or lisinopril 10-40mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83mm Hg (27% control) to 134/ 76mm Hg (chlorthalidone, 68% control), 135/75mm Hg (amlodipine, 66% control), and 136/76mm Hg (lisinopril, 61% control) by 5years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP <140/90mm Hg in a majority of patients.

AB - Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9years) by randomized groups: chlorthalidone, 12.5-25mg/d (n=15,255), amlodipine 2.5-10mg/d (n=9048), or lisinopril 10-40mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83mm Hg (27% control) to 134/ 76mm Hg (chlorthalidone, 68% control), 135/75mm Hg (amlodipine, 66% control), and 136/76mm Hg (lisinopril, 61% control) by 5years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP <140/90mm Hg in a majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=58949098039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949098039&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7176.2008.00015.x

DO - 10.1111/j.1751-7176.2008.00015.x

M3 - Article

C2 - 19090876

AN - SCOPUS:58949098039

VL - 10

SP - 751

EP - 760

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 10

ER -